Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors

por Ando, Yuichi, Iwasa, Satoru, Takahashi, Shunji, Saka, Hideo, Kakizume, Tomoyuki, Natsume, Kazuto, Suenaga, Naoko, Quadt, Cornelia, Yamada, Yasuhide
Publicado 2019

Phase I dose-escalation study of buparlisib (BKM120), an oral pan-class I PI3K inhibitor, in Japanese patients with advanced solid tumors

por Ando, Yuichi, Inada-Inoue, Megumi, Mitsuma, Ayako, Yoshino, Takayuki, Ohtsu, Atsushi, Suenaga, Naoko, Sato, Masahiko, Kakizume, Tomoyuki, Robson, Matthew, Quadt, Cornelia, Doi, Toshihiko
Publicado 2014

Phase I Study of Ceritinib (LDK378) in Japanese Patients with Advanced, Anaplastic Lymphoma Kinase-Rearranged Non–Small-Cell Lung Cancer or Other Tumors

por Nishio, Makoto, Murakami, Haruyasu, Horiike, Atsushi, Takahashi, Toshiaki, Hirai, Fumihiko, Suenaga, Naoko, Tajima, Takeshi, Tokushige, Kota, Ishii, Masami, Boral, Anthony, Robson, Matthew, Seto, Takashi
Publicado 2015